Lundgren R, Sundin T, Colleen S, Lindstedt E, Wadström L, Carlsson S, Hellsten S, Pompeius R, Holmquist B, Nilsson T
Scand J Urol Nephrol. 1986;20(2):101-5. doi: 10.3109/00365598609040556.
In a prospective multicenter study, 244 men with highly or moderately differentiated prostatic cancer in stage I, II or III (VACURG) were consecutively randomized to three groups of treatment: Group A (77 patients) received polyestradiol phosphate (Estradurin, Leo) 80 mg i.m. every fourth week + ethinyl estradiol (Etivex, Leo) 150 micrograms daily, group B (72 patients) estramustine phosphate (Estracyt, Leo) 280 mg twice daily, and group C (76 patients) no therapy. Only men without current or previous other malignancy and without cardiovascular disease were admitted to the study. After 4 1/2 years 125 of the 244 patients had left the study, 9 because of cancer progression (stage IV, VACURG). The most serious complications were cardiovascular, including ischemic heart disease, cardiac decompensation, cerebral ischemia and venous thromboembolism, which occurred in 24 patients from group A and 9 from group B as compared to only one patient in group C. The subgroup superficial or deep venous thrombosis comprised 11 group A and 2 group B patients. Estrogens (E + e) offered as palliative treatment to patients with non-generalized prostatic carcinoma is burdened with a high incidence of serious cardiovascular complications.
在一项前瞻性多中心研究中，244例I、II或III期高分化或中分化前列腺癌男性患者（VACURG）被连续随机分为三组进行治疗：A组（77例患者）每四周肌肉注射80毫克磷酸聚雌二醇（利奥公司的Estradurin）+每日口服150微克炔雌醇（利奥公司的Etivex）；B组（72例患者）每日两次口服280毫克磷酸雌莫司汀（利奥公司的Estracyt）；C组（76例患者）不接受治疗。只有目前或既往无其他恶性肿瘤且无心血管疾病的男性被纳入研究。4年半后，244例患者中有125例退出研究，9例因癌症进展（IV期，VACURG）退出。最严重的并发症是心血管方面的，包括缺血性心脏病、心脏代偿失调、脑缺血和静脉血栓栓塞，A组有24例患者出现这些并发症，B组有9例，而C组只有1例。浅静脉或深静脉血栓形成亚组中，A组有11例患者，B组有2例患者。作为非广泛性前列腺癌患者姑息治疗的雌激素（E+e）会带来严重心血管并发症的高发生率。
